Phathom Pharmaceuticals Inc

NASDAQ:PHAT   3:59:43 PM EDT
42.72
-0.15 (-0.35%)
Earnings Announcements

Phathom Pharmaceuticals Provides Update On Phase 3 Trials

Published: 11/10/2020 21:29 GMT
Phathom Pharmaceuticals, Inc. (PHAT) - Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials.
Phathom Pharmaceuticals Inc - As of September 30, 2020, Cash and Cash Equivalents Were $226.4 Million.
Phathom Pharmaceuticals Inc - Qtrly Loss per Share $1.02.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.99

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.30

More details on our Analysts Page.